Patents Assigned to Umbra Therapeutics, Inc.
  • COVALENT KRAS-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES
    Publication number: 20230406854
    Abstract: Heteroaryl sulfonyl compounds and compositions that have a KRAS Recognition Moiety bound to an electrophile for the selective covalent modification of KRAS, for example a mutant KRAS, to treat KRAS-mediated disorders are described.
    Type: Application
    Filed: September 5, 2023
    Publication date: December 21, 2023
    Applicant: Umbra Therapeutics, Inc.
    Inventors: Guillaume Barbe, Mark George Sauliner, William John Greenlee, Soumya Ray
  • COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES
    Publication number: 20230406853
    Abstract: Heteroaryl sulfonyl compounds and compositions that have a CDK2 Recognition Moiety bound to an electrophile for the selective covalent modification of CDK2 to treat CDK2-mediated disorders are described.
    Type: Application
    Filed: September 5, 2023
    Publication date: December 21, 2023
    Applicant: Umbra Therapeutics, Inc.
    Inventors: Guillaume Barbe, Mark George Sauliner, William John Greenlee, Soumya Ray